Gainers
- Citius Oncology CTOR shares rose 46.4% to $5.12 during Friday's regular session. The market value of their outstanding shares is at $250.4 million.
- Eyenovia EYEN shares increased by 43.97% to $11.36. The company's market cap stands at $22.7 million.
- Citius Pharmaceuticals CTXR shares moved upwards by 30.88% to $1.74. The market value of their outstanding shares is at $14.4 million.
- I-MAB IMAB shares increased by 27.72% to $2.58. The company's market cap stands at $163.3 million.
- Vor Biopharma VOR stock moved upwards by 27.52% to $1.14. The company's market cap stands at $111.2 million.
- GlucoTrack GCTK stock rose 27.39% to $6.65. The company's market cap stands at $2.9 million.
Losers
- Ontrak OTRK stock decreased by 44.1% to $0.54 during Friday's regular session. The market value of their outstanding shares is at $4.1 million.
- Liminatus Pharma LIMN shares fell 39.82% to $9.99. The company's market cap stands at $431.8 million.
- Achieve Life Sciences ACHV stock declined by 37.32% to $2.2. The company's market cap stands at $121.7 million.
- Aethlon Medical AEMD stock fell 34.54% to $1.27. The company's market cap stands at $3.9 million. The company's, Q4 earnings came out yesterday.
- Lyra Therapeutics LYRA stock decreased by 29.83% to $9.39. The company's market cap stands at $17.7 million.
- Adial Pharmaceuticals ADIL shares fell 29.08% to $0.33. The company's market cap stands at $7.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ACHVAchieve Life Sciences Inc
$2.781.09%
Edge Rankings
Momentum
15.47
Price Trend
Short
Medium
Long
ADILAdial Pharmaceuticals Inc
$0.4423-1.71%
AEMDAethlon Medical Inc
$1.291.57%
CTORCitius Oncology Inc
$1.57-1.88%
CTXRCitius Pharmaceuticals Inc
$1.600.31%
GCTKGlucoTrack Inc
$6.001.35%
IMABI-MAB
$2.16-%
LIMNLiminatus Pharma Inc
$5.724.57%
LYRALyra Therapeutics Inc
$8.32-2.69%
OTRKOntrak Inc
$0.5251-2.76%
VORVor Biopharma Inc
$2.473.78%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.